Cost-consequence analysis for recombinant human growth hormone treatment administered via different devices in children in Spain

Comparing height gain and treatment costs of the treatment with recombinant human growth hormone (r-hGH), administered either by Easypod® or other conventional devices licensed in Spain (non-Easypod®) in children and adolescents with growth hormone deficiency.

Authors: Alcón Sáez, José Juan; De Arriba Muñoz, Antonio; Latre Gorbe, Cristina; Pérez-Carbonell, Lucía; Villalobos, Triana; Durán Morán, Olga

Journal: Revista Española de economía de la Salud (EDS)

Year: 2022

Subscribe to Outcomes´10

Name *

E-mail *

Todos los campos marcados con un * son obligatorios

Responsible for the data: Outcomes'10, s.l.u., Purpose: Sending commercial communications. Legitimation: Art. 6.1 Consent of the interested party. Recipient: No data is transferred unless expressly authorised. You may exercise your rights on data protection (access, rectification, opposition, deletion, automated decisions, limitation of treatment, portability) by email at dpo@outcomes10.com. Data will be retained for the time necessary to fulfill its purpose and derived responsibilities by current regulations and the deadlines in the applicable regulations on archives and documentation. In any case, you can request the protection of the Spanish Data Protection Agency through its website www.aepd.es/. In addition, you can consult more information on the privacy policy

I have read and accepted the privacy policy